Chiesi to acquire KalVista for $1.9 billion in rare disease expansion

April 29, 2026 7:42 AM

Chiesi Group announced it will acquire KalVista Pharmaceuticals Inc. (NASDAQ: KALV) for $27.00 per share in cash, representing approximately $1.9 ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found